Background
Methods
Patients
Microbial aetiology
Clinical outcomes
Resource utilization and cost calculation
Data analyses
Results
Characteristics | All patients (n = 505) |
---|---|
Age in years (SD) | 63.4 (18.0) |
Male sex (%) | 295 (58.4) |
Comorbidities (%) | |
Chronic obstructive pulmonary disease | 98 (19.4) |
Congestive heart failure | 68 (13.5) |
Renal disease | 40 (7.9) |
Diabetes mellitus | 77 (15.2) |
Liver disease | 2 (0.4) |
Pneumonia Severity Index class I-III (%) | 279 (55.2) |
Pneumonia Severity Index class IV-V (%) | 226 (44.8) |
Pathogens (%) | |
Streptococcus pneumoniae
| 124 (24.6) |
Coxiella burnetii
| 28 (5.5) |
Haemophilus influenzae
| 27 (5.3) |
Legionella pneumophila
| 20 (4.0) |
Chlamydophila species | 16 (3.2) |
Mycoplasma pneumoniae
| 9 (1.8) |
Staphylococcus aureus
| 9 (1.8) |
Only viral pathogen | 35 (6.9) |
Other pathogen | 27 (5.3) |
No pathogen identified | 210 (41.6) |
Empirical antibiotic treatment (%) | |
Beta-lactam, penicillins (monotherapy) | 254 (50.3) |
Other beta-lactam (monotherapy) | 86 (17.0) |
Beta-lactam, penicillins + quinolone | 34 (6.7) |
Beta-lactam, penicillins + macrolides | 33 (6.5) |
Other beta-lactam + aminoglycoside | 20 (4.0) |
Other beta-lactam + quinolone | 16 (3.2) |
Quinolone (monotherapy) | 11 (2.2) |
Macrolides, lincosamides and streptogramins (monotherapy) | 11 (2.2) |
Beta-lactam, penicillin + aminoglycoside | 7 (1.4) |
Other beta-lactam, penicillin + macrolides | 7 (1.4) |
Sulfanomides and trimethoprim (monotherapy) | 6 (1.2) |
Tetracyclines (monotherapy) | 6 (1.2) |
Other | 14 (2.8) |
Outcomes | |
Length of hospital stay (IQR) | 8.5 (6.0-13.0) |
Intensive care unit admission (%) | 38 (7.5) |
In-hospital mortality (%) | 24 (4.8) |
30-Day mortality (%) | 26 (5.1) |
One-year mortality (%) | 73 (14.5) ⟂
|
Aetiology and clinical outcomes
Sputum culture | Sputum PCR | Blood culture | Blood PCR | Urinary antigen test | Serology | |
---|---|---|---|---|---|---|
S. pneumoniae n = 124 | 46 | - | 42 | - | 78 | 1 |
Haemophilus influenzae n = 27 | 25 | 1 | - | - | - | 1 |
Legionella pneumophila n = 20 | 1 | 3 | - | - | 15 | 6 |
Mycoplasma pneumoniae n = 9 | - | 4 | - | - | - | 7 |
Coxiella burnetii n = 28 | 1 | 12 | 2 | 12 | - | 20 |
Chlamydophila spp. n = 16 | - | 8 | - | - | - | 12 |
Staphylococcus aureus n = 9 | 8 | - | 1 | - | - | - |
Other pathogen n = 27 | 23 | - | 5 | - | - | - |
Viral pathogen n = 35 | 3 | 2 | - | - | - | 19 |
Length of hospital stay (IQR) | ICU admission (%) | In-hospital mortality (%) | 30-day mortality (%) | One-year mortality (%) | |
---|---|---|---|---|---|
Streptococcus pneumoniae (n = 124) | 8.5 (6.5-14.9) | 10 (8.1) | 4 (3.2) | 4 (3.2) | 12 (9.7) |
Coxiella burnetii (n = 28) | 5.5 (3.5-7.5) | 0 | 0 | 1 (3.6) | 1 (3.6) |
Haemophilus Influenzae (n = 27) | 9.0 (7.5-14.0) | 2 (7.4) | 0 | 0 | 3 (11.1) |
Legionella pneumophila (n = 20) | 11.0 (6.5-17.0) | 3 (15.0) | 1 (5.0) | 1 (5.0) | 2 (10.0) |
Chlamydophila species (n = 16) | 8.5 (6.6-13.3) | 2 (12.5) | 0 | 0 | 1 (6.3) |
Mycoplasma pneumoniae (n = 9) | 5.0 (4.5-7.3) | 0 | 0 | 0 | 0 |
Staphylococcus aureus (n = 9) | 10.5 (7.3-14.5) | 1 (11.1) | 3 (33.3) | 3 (33.3) | 4 (44.4) |
Other pathogen (n = 27) | 8.0 (5.0-15.8) | 7 (25.9) | 2 (7.4) | 2 (7.4) | 9 (33.3) |
Viral pathogen (n = 35) | 8.5 (6.3-13.5) | 1 (2.9) | 2 (5.7) | 3 (8.6) | 6 (17.1) |
No pathogen found (n = 210) | 8.5 (5.5-12.6) | 12 (5.7) | 12 (5.7) | 12 (5.7) | 35 (16.7) |
Hospital costs
Total costs
Resource | Mean frequency per patient | Price per item (in euro) | |
---|---|---|---|
10 Most frequent resource items
| |||
1
| Tissue obtainment (microbiology and clinical chemistry) | 18.1 | 13.73 |
2
| Antibodies against any pathogen by using complement fixation test of haemagglutination inhibition essay | 10.4 | 4.84 |
3
| General ward nursing (one day) | 9.4 | 375.00 |
4
| Sodium | 8.2 | 1.76 |
5
| Potassium | 8.2 | 1.76 |
6
| Creatinine | 6.6 | 1.76 |
7
| Glucose | 6.4 | 1.76 |
8
| Leukocytes | 6.1 | 1.76 |
9
| C-reactive protein | 6.0 | 4.84 |
10
| Urea | 5.9 | 1.76 |
10 Most expensive resource items
| |||
1
| Intensive care unit nursing (one day) | 0.6 | 1,730.00 |
2
| Surgical treatment of thorax empyema | 0.2 | 1,084.75 |
3
| Laryngoscopy | 0.0 | 999.00 |
4
| Microbiological determination on isolated DNA/RNA | 0.0 | 867.61 |
5
| General ward nursing (one day) | 9.4 | 375.00 |
6
| Flexible bronchoscopy | 0.2 | 209.25 |
7
| DNA/RNA amplification (qualitative) | <0.1 | 208.60 |
8
| Computer tomography of thorax | 0.2 | 195.83 |
9
| Immunopathologic research | <0.1 | 109.57 |
10
| Computer tomography airways | <0.1 | 160.01 |
Costs categorized per aetiological group
Costs per S. pneumoniaeserotype
Identification of cost driving factors
Crude analysis | Multivariable analysis | |||||
---|---|---|---|---|---|---|
Independent variables | B | SE | p-value | B | SE | p-value |
CONSTANT |
3.558
|
0.023
|
<0.001
| |||
Male gender | 0.009 | 0.032 | 0.77 | |||
Chronic obstructive pulmonary disease | 0.009 | 0.044 | 0.83 | |||
Congestive heart failure |
0.083
|
0.045
|
0.06
| |||
Chronic renal disease | 0.077 | 0.057 | 0.17 | |||
Diabetes mellitus | 0.047 | 0.045 | 0.30 | |||
Pneumonia Severity Index classes IV-V |
0.176
|
0.030
|
<0.001
|
0.158
|
0.030
|
<0.001
|
Hospital ‘Gelderse Vallei’ | −0.063 | 0.042 | 0.13 | |||
Pathogens: | ||||||
Streptococcus pneumoniae
|
0.070
|
0.038
|
0.07
|
0.067
|
0.036
|
0.07
|
Coxiella burnetii
|
−0.198
|
0.058
|
0.001
|
−0.129
|
0.056
|
0.02
|
Haemophilus influenzae
| −0.047 | 0.087 | 0.59 | |||
Legionella pneumophila
| 0.060 | 0.076 | 0.43 | |||
Chlamydophila species | 0.087 | 0.076 | 0.25 | |||
Mycoplasma pneumoniae
| −0.179 | 0.134 | 0.18 | |||
Staphylococcus aureus
|
0.358
|
0.148
|
0.02
|
0.362
|
0.140
|
0.01
|
Viral pathogen | −0.046 | 0.064 | 0.48 | |||
Other pathogen |
0.163
|
0.073
|
0.03
|
0.131
|
0.070
|
0.06
|
No pathogen found | −0.034 | 0.031 | 0.28 |